Page 21 - Read Online

Tumor grafts derived from women with breast cancer 54. Meads MB, Gatenby RA, Dalton WS. Environment-mediated
authentically refl ect tumor pathology, growth, metastasis and drug resistance: A major contributor to minimal residual
disease outcomes. Nat Med 2011;17:1514-20. disease. Nat Rev Cancer 2009;9:665-74.
39. Zhao X, Liu Z, Yu L, Zhang Y, Baxter P, Voicu H, 55. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN,
Gurusiddappa S, Luan J, Su JM, Leung HC, Li XN. Global Kahnoski R, Futreal PA, Furge KA, Teh BT. Interleukin-8
gene expression profi ling confi rms the molecular fi delity of mediates resistance to antiangiogenic agent sunitinib in renal
primary tumor-based orthotopic xenograft mouse models of cell carcinoma. Cancer Res 2010;70:1063-71.
medulloblastoma. Neuro Oncol 2012;14:574-83. 56. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO,
40. McEvoy J, Ulyanov A, Brennan R, Wu G, Pounds S, Zhang J, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD,
Dyer MA. Analysis of MDM2 and MDM4 single nucleotide Christensen JG. HGF/c-Met acts as an alternative angiogenic
polymorphisms, mRNA splicing and protein expression in pathway in sunitinib-resistant tumors. Cancer Res
retinoblastoma. PLoS One 2012;7:e42739. 2010;70:10090-100.
41. Morton CL, Houghton PJ. Establishment of human 57. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH,
tumor xenografts in immunodefi cient mice. Nat Protoc Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U,
2007;2:247-50. Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE,
42. Goda K, Bacsó Z, Szabó G. Multidrug resistance through Benezra R, Kerbel RS. Rapid chemotherapy-induced acute
the spectacle of P-glycoprotein. Curr Cancer Drug Targets endothelial progenitor cell mobilization: Implications for
2009;9:281-97. antiangiogenic drugs as chemosensitizing agents. Cancer Cell
43. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, 2008;14:263-73.
cancer, and cancer stem cells. Nature 2001;414:105-11. 58. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic
44. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, therapy. Nat Rev Cancer 2008;8:592-603.
Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, 59. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A,
Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, McIntyre D, Honess D, Madhu B, Goldgraben MA,
Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C,
Clarke MF. Association of reactive oxygen species levels and Combs C, Winter SP, Ireland-Zecchini H, Reichelt S,
radioresistance in cancer stem cells. Nature 2009;458:780-3. Howat WJ, Chang A, Dhara M, Wang L, Ruckert F,
45. Zhou J, Zhang Y. Cancer stem cells: Models, mechanisms Grutzmann R, Pilarsky C, Izeradjene K, Hingorani SR,
and implications for improved treatment. Cell Cycle Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH,
2008;7:1360-70. Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C,
46. Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Griffi ths J, Tuveson DA. Inhibition of Hedgehog signaling
enhances delivery of chemotherapy in a mouse model of
Spratt DE, Chung CH, Lu B. Targeting the mechanisms of pancreatic cancer. Science 2009;324:1457-61.
resistance to chemotherapy and radiotherapy with the cancer
stem cell hypothesis. J Oncol 2011;2011:941876. 60. Krumbach R, Schüler J, Hofmann M, Giesemann T,
Fiebig HH, Beckers T. Primary resistance to cetuximab in a
47. Hammerman PS, Jänne PA, Johnson BE. Resistance to panel of patient-derived tumour xenograft models: Activation
epidermal growth factor receptor tyrosine kinase inhibitors in of MET as one mechanism for drug resistance. Eur J Cancer
non-small cell lung cancer. Clin Cancer Res 2009;15:7502-509. 2011;47:1231-43.
48. Lee JC, Jang SH, Lee KY, Kim YC. Treatment of non-small 61. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J,
cell lung carcinoma after failure of epidermal growth Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW,
factor receptor tyrosine kinase inhibitor. Cancer Res Treat Oliner KS, Vogelstein B. The molecular evolution of acquired
2013;45:79-85. resistance to targeted EGFR blockade in colorectal cancers.
49. Ogino A, Kitao H, Hirano S, Uchida A, Ishiai M, Kozuki T, Nature 2012;486:537-40.
Takigawa N, Takata M, Kiura K, Tanimoto M. Emergence 62. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y,
of epidermal growth factor receptor T790M mutation during Turashvili G, Ding J, Tse K, Haffari G, Bashashati A,
chronic exposure to gefi tinib in a non small cell lung cancer Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V,
cell line. Cancer Res 2007;67:7807-14. McPherson A, Shumansky K, Crisan A, Giuliany R,
50. Sadiq AA, Salgia R. MET as a possible target for Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A,
non-small-cell lung cancer. J Clin Oncol 2013;31:1089-96. Dhalla N, Zeng T, Ma K, Chan SK, Griffi th M, Moradian A,
51. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF,
Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J,
Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P,
Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW,
Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA,
Halmos B, Bivona TG. Activation of the AXL kinase causes Aparicio S. The clonal and mutational evolution spectrum of
resistance to EGFR-targeted therapy in lung cancer. Nat Genet primary triple-negative breast cancers. Nature 2012;486:395-9.
2012;44:852-60. 63. Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, Gallick GE,
52. Nurwidya F, Takahashi F, Murakami A, Takahashi K. Wang H, McConkey DJ, Hwang R, Logsdon C, Abbruzzesse J,
Epithelial mesenchymal transition in drug resistance and Fleming JB. Molecular profi ling of direct xenograft tumors
metastasis of lung cancer. Cancer Res Treat 2012;44:151-6. established from human pancreatic adenocarcinoma after
53. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, neoadjuvant therapy. Ann Surg Oncol 2012;19 Suppl 3:S395-403.
Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, 64. Dong X, Guan J, English JC, Flint J, Yee J, Evans K,
Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Murray N, Macaulay C, Ng RT, Gout PW, Lam WL, Laskin J,
Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Ling V, Lam S, Wang Y. Patient-derived fi rst generation
Iafrate AJ, Mino-Kenudson M, Engelman JA. Genotypic and xenografts of non-small cell lung cancers: Promising tools
histological evolution of lung cancers acquiring resistance to for predicting drug responses for personalized chemotherapy.
EGFR inhibitors. Sci Transl Med 2011;3:75ra26. Clin Cancer Res 2010;16:1442-51.

14 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 1 ¦ April 15, 2015 ¦